A prospective pilot study was carried out on 34 CLL patients treated with ibrutinib, evaluating the effects on symptoms and physical function with changes in plasma exosomes (EXs), β2-microglobulin (β2M) and 26 plasma cytokines. The revised Edmonton Symptom Assessment Scale (ESAS-R) demonstrated moderate fatigue, shortness of breath and a sense of unwellness before treatment, which significantly improved within 2 weeks of starting ibrutinib. These changes were associated with a rapid improvement in sit-to-stand and 4 m walking speeds. The plasma levels of CCL11, IL-7, -8 and -10 dropped initially while the levels of TNF-α/-β, CCL3, CCL4, CCL17, and IL-16 continued to decline for 12 months. Despite the initial lymphocytosis, plasma β2M levels fell but no consistent change in plasma EXs occurred. Thus, ibrutinib can produce a rapid and sustained improvement in symptoms and physical function in CLL, associated with a decline in multiple plasma cytokines.

一项前瞻性试点研究对 34 名接受依鲁替尼治疗的 CLL 患者进行，评估血浆外泌体 (EXs)、β2-微球蛋白 (β2M) 和 26 种血浆细胞因子的变化对症状和身体功能的影响。修订后的埃德蒙顿症状评估量表 (ESAS-R) 在治疗前表现出中度疲劳、气短和不适感，在开始依鲁替尼治疗后 2 周内显着改善。这些变化与从坐到站和 4 m 步行速度的快速改善有关。CCL11、IL-7、-8和-10的血浆水平最初下降，而TNF-α/-β、CCL3、CCL4、CCL17和IL-16的水平持续下降12个月。尽管初始淋巴细胞增多，血浆 β2M 水平下降但血浆 EX 没有发生一致的变化。因此，